In HCC patients, the PFS curve for patients with Child-Pugh A status appears to have a longer tail compared to that for patients with Child-Pugh B status with similar mPFS (3.8 [95 % CI:3.4–15.9] vs. 3.0 [95 % CI:1.8–3.6] months); HCC patients with at least one prior anti-VEGF therapy (n = 8) achieved longer mPFS compared to those without any prior anti-VEGF therapy (n = 12) (15.9 [95 % CI: 1.7–15.9] vs. 3.5 [95 % CI: 3.0–7.4] months), although small numbers prevent direct comparison. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.